Latest Strategic Shift News

BlackWall Limited posted a $2.4 million statutory loss for FY2026, driven by operating setbacks and unrealised asset write-downs. The company suspends dividends after exhausting franking credits and proposes a share buy-back offering WOT securities in lieu of cash.

Hubify Limited posted an 89% jump in FY26 EBITDA to $0.66 million despite a 5% revenue dip, driven by a strategic shift to higher-margin managed technology and advisory services and a robust cash position of $3.79 million.

Raiz Invest posted a 21% revenue jump and a 93% surge in underlying EBITDA for FY26, marking a return to profitability amid a CEO transition and a strategic shift towards a broader wealth platform.

Genesis Energy posted a robust FY26 with Normalised EBITDAF up 11% to $522m, driven by margin growth and strategic investments in renewables and battery storage. A $400m equity raise bolstered its balance sheet as it accelerates New Zealand’s energy transition.

Pengana Capital Group reported a statutory loss of $5.6 million for FY26 despite a 14% rise in funds under management, driven by upfront costs linked to new product launches and expanding private credit platforms.

Resimac Group Ltd delivered a 42% jump in statutory profit for FY26 despite flat revenue, driven by strong home loan growth and improved margins, while raising its final dividend to 6 cents per share.

BCAL Diagnostics has increased its shareholding in Genetic Signatures to nearly a fifth, aiming to leverage infectious disease technology to complement its cancer detection portfolio.

Camplify Holdings slashed its net loss by 95% in FY26, posting a second-half profit driven by cost cuts and the MyWay Mutual insurance launch, setting a foundation for growth in FY27.

Veris Limited lifted revenue by 4.9% to $102 million in FY26, driven by digital and advisory growth, but statutory net profit fell 67% amid one-off costs and macroeconomic headwinds.

Steel & Tube Holdings reported a 13.9% revenue rise and a 376% jump in normalised EBITDA for FY26, despite a statutory net loss of NZD 61.2 million driven by significant asset impairments and ongoing market challenges.

NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.

Embelton Limited has reported a solid 20.4% increase in revenue and a 34.7% jump in profit after tax for FY2026, underpinned by a strategic pivot away from residential construction towards infrastructure and social sectors. The company held its dividend steady amid improving cash flow and reduced borrowings.